Corrigendum: Sevoflurane Alleviates Myocardial Ischemia Reperfusion Injury by Inhibiting P2X7-NLRP3 Mediated Pyroptosis

Abstract

There is an error in the Funding statement. The correct number for "the National Natural Science Foundation of China" is " 81473215 and 81870276".Additionally, in the original article, there was a mistake in "Figures 2-4" as published. The problem was caused by the incomplete uploading of some figures in the process of uploading revised manuscripts and figures before publication. We did not carefully check it, which led to the error when publishing the article. The correct figures appear below:Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Research Progress on the Role of Pyroptosis in Myocardial Ischemia-Reperfusion Injury

“…Several studies have demonstrated that sevoflurane has a protective effect on MIRI by suppressing the inflammatory response. A review by Wu et al indicated that the inhibition of cardiomyocyte inflammation and pyroptosis by regulation of the P2X7-NLRP3 signaling pathway is a potential mechanism of sevoflurane against MIRI [ 113 ]. Briefly, it was observed that sevoflurane treatment suppressed the high expressions of P2X7, NLRP3, ASC, caspase-1, and GSDMD and the release of LDH, CK, CK-MB, and MDA in the cells, and increased the activity of SOD.…”